Dupilumab and subcutaneous immunotherapy for the treatment of refractory moderate to severe atopic dermatitis: A preliminary report

•Atopic dermatitis significantly affects patients’ quality of life.•Some patients are resistant to monotherapy for atopic dermatitis.•Combining dupilumab and subcutaneous immunotherapy may improve patients’ responses. Subcutaneous immunotherapy (SCIT) and dupilumab are important treatments for patie...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	International immunopharmacology 2023-12, Vol.125 (Pt A), p.111137-111137, Article 111137
Hauptverfasser:	Deng, Sisi, Wang, Huan, Chen, Shuguang, Kong, Minmin, Yang, Xianjie, Song, Zhiqiang, Chen, Qiquan
Format:	Artikel
Sprache:	eng
Schlagworte:	Atopic dermatitis Dermatitis, Atopic - drug therapy Desensitization, Immunologic Double-Blind Method Dupilumab Humans Immunoglobulin E Injections, Subcutaneous Retrospective Studies Severity of Illness Index Subcutaneous immunotherapy Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!